Geron(US:GERN) Globenewswire·2025-10-23 22:14Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Geron Corporation on behalf of long-term stockholders following a class action complaint filed against Geron, focusing on possible breaches of fiduciary duties by the board of directors [2][3]. Group 1: Legal Investigation - The class action complaint against Geron was filed on March 14, 2025, with a class period from February 28, 2024, to February 25, 2025 [2]. - The investigation centers on whether Geron's board of directors has breached their fiduciary duties to the company [2]. Group 2: Allegations in the Complaint - The complaint alleges that throughout the class period, Geron's executives provided misleading information regarding the launch and growth potential of Rytelo (imetelstat) [3]. - It is claimed that the executives expressed confidence in Geron's ability to meet the significant unmet need for the drug while downplaying risks associated with weekly monitoring requirements and competition [3]. Group 3: Next Steps for Investors - Long-term stockholders of Geron are encouraged to contact Bragar Eagel & Squire for more information regarding the claims and their rights [4]. - The firm offers a no-cost consultation for those interested in discussing their legal options [4]. Group 4: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation [5]. - The firm operates in multiple states, including New York, South Carolina, and California [5].